Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT05445778)

🧪 Interventions in This Study

• Mirvetuximab soravtansine plus Bevacizumab (DRUG)
• Bevacizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (264 Sites)

Showing the first 25 of 264 sites.

• Usa Mitchell Cancer Institute /ID# 269661 — Mobile, Alabama
• Honorhealth Virginia G. Piper Cancer Care Network - Biltmore /ID# 269987 — Phoenix, Arizona
• City of Hope - Orange County Lennar Foundation Cancer Center /ID# 269573 — Irvine, California
• Moores Cancer Center at UC San Diego /ID# 269564 — La Jolla, California
• Kaiser Permanente - Los Angeles Medical Center /ID# 269541 — Los Angeles, California
• University Of California Irvine Medical Center /ID# 269572 — Orange, California
• Stanford Women'S Cancer Center /ID# 269552 — Palo Alto, California
• Kaiser Permanente - Riverside Medical Center /ID# 269539 — Riverside, California
• Kaiser Permanente Zion Medical Center /ID# 269537 — San Diego, California
• Kaiser Permanente - San Diego Medical Center /ID# 269540 — San Diego, California
• Kaiser Permanente - San Marcos Medical Offices /ID# 269542 — San Marcos, California
• Olive View-Ucla Medical Center /ID# 269584 — Sylmar, California
• John Muir Health - Walnut Creek Medical Center /ID# 269575 — Walnut Creek, California
• Broward General Medical Center /ID# 269577 — Fort Lauderdale, Florida
• Regional Cancer Center /ID# 269558 — Fort Myers, Florida
• Baptist Md Anderson Cancer Center - Jacksonville - Palm Avenue /ID# 269560 — Jacksonville, Florida
• Mount Sinai Medical Center /ID# 269582 — Miami, Florida
• Sarasota Memorial Hospital /ID# 269526 — Sarasota, Florida
• Northside Hospital /ID# 269660 — Atlanta, Georgia
• Rush University Medical Center /ID# 269583 — Chicago, Illinois
• University of Chicago Medical Center /ID# 269546 — Chicago, Illinois
• Indiana University Melvin and Bren Simon Comprehensive Cancer Center /ID# 269110 — Indianapolis, Indiana
• St. Vincent Indianapolis Hospital /ID# 269107 — Indianapolis, Indiana
• University of Iowa /ID# 269566 — Iowa City, Iowa
• The University of Kansas Cancer Center - Westwood /ID# 269106 — Westwood, Kansas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Ovarian Cancer

• Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
• Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
• Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
• Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
• NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts

Explore by condition: All Ovarian Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.